Europe Dengue Treatment Market

List of Tables

Europe dengue treatment market is expected to reach 174.28 million by 2031, from USD 83.46 million in 2023, growing at the CAGR of 9.6% in the forecast period of 2024 to 2031.

Market Segmentation:

Europe Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, and Rest of Europe) - Industry Trends and Forecast to 2031

Overview of Europe Dengue Treatment Market Dynamics:

Driver
Rising dengue incidence rate result in the demand for effective treatment
Restrain
Delay in the approval process of vaccines
Opportunity
Growing number of pipeline vaccines for dengue treatment

Market Players:

The key market players operating in the Europe dengue treatment market are listed below:

Sanofi
Takeda Pharmaceutical Company Limited
Viatris Inc.
Johnson & Johnson
GSK plc.
Perrigo Company PLC
Baxter
Fresenius Kabi USA
Pfizer
Hikma Pharmaceuticals PLC
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA, Inc.
Aurobindo Pharma

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE DENGUE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.10 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES

5 EUROPE DENGUE TREATMENT MARKET: REGULATIONS

5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK

6 MARKET OVERVIEW

6.1 DRIVERS
- 6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT
- 6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES
- 6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
- 6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
6.2 RESTRAINTS
- 6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES
- 6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE
- 6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE
6.3 OPPORTUNITIES
- 6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET
- 6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT
- 6.3.3 RISING R&D INVESTMENT AND ACTIVITIES
6.4 CHALLENGES
- 6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS
- 6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS

7 EUROPE DENGUE TREATMENT MARKET, BY STRAINS

7.1 OVERVIEW
7.2 DENV-2
7.3 DENV-3
7.4 DENV-1
7.5 DENV-4
7.6 OTHERS

8 EUROPE DENGUE TREATMENT MARKET, BY TYPE

8.1 OVERVIEW
8.2 VACCINES
- 8.2.1 DENGVAXIA (CYD-TDV)
- 8.2.2 QDENGA
8.3 ACETAMINOPHEN
- 8.3.1 PARENTERAL
- 8.3.2 ORAL
- 8.3.3 OTHER

9 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY

9.1 OVERVIEW
9.2 MILD TO MODERATE DENGUE
9.3 SEVERE DENGUE

10 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW
10.2 PARENTERAL
- 10.2.1 SUB-CUTANEOUS
- 10.2.2 INTRAVENOUS
10.3 ORAL
- 10.3.1 TABLET
- 10.3.2 CAPSULES
- 10.3.3 OTHERS

11 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE

11.1 OVERVIEW
11.2 PRESCRIPTION
11.3 OVER-THE-COUNTER (OTC)

12 EUROPE DENGUE TREATMENT MARKET, BY GENDER

12.1 OVERVIEW
12.2 MALE
12.3 FEMALE

13 EUROPE DENGUE TREATMENT MARKET, BY AGE

13.1 OVERVIEW
13.2 ADULT
13.3 PEDIATRIC
13.4 GERIATRIC

14 EUROPE DENGUE TREATMENT MARKET, BY END USER

14.1 OVERVIEW
14.2 HOSPITAL
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS

15 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW
15.2 RETAIL PHARMACIES
15.3 HOSPITAL PHARMACIES
15.4 ONLINE PHARMACIES

16 EUROPE DENGUE TREATMENT MARKET, BY REGION

16.1 EUROPE
- 16.1.1 FRANCE
- 16.1.2 GERMANY
- 16.1.3 SPAIN
- 16.1.4 U.K.
- 16.1.5 BELGIUM
- 16.1.6 ITALY
- 16.1.7 NETHERLANDS
- 16.1.8 RUSSIA
- 16.1.9 SWITZERLAND
- 16.1.10 TURKEY
- 16.1.11 REST OF EUROPE

17 EUROPE DENGUE TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: EUROPE

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 SANOFI
- 19.1.1 COMPANY SNAPSHOT
- 19.1.2 REVENUE ANALYSIS
- 19.1.3 COMPANY SHARE ANALYSIS
- 19.1.4 PRODUCT PORTFOLIO
- 19.1.5 RECENT DEVELOPMENTS
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 19.2.1 COMPANY SNAPSHOT
- 19.2.2 REVENUE ANALYSIS
- 19.2.3 COMPANY SHARE ANALYSIS
- 19.2.4 PRODUCT PORTFOLIO
- 19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
- 19.3.1 COMPANY SNAPSHOT
- 19.3.2 REVENUE ANALYSIS
- 19.3.3 COMPANY SHARE ANALYSIS
- 19.3.4 PRODUCT PORTFOLIO
- 19.3.5 RECENT DEVELOPMENTS
19.4 JOHNSON & JOHNSON SERVICES, INC.
- 19.4.1 COMPANY SNAPSHOT
- 19.4.2 REVENUE ANALYSIS
- 19.4.3 COMPANY SHARE ANALYSIS
- 19.4.4 PRODUCT PORTFOLIO
- 19.4.5 RECENT DEVELOPMENT
19.5 GSK PLC.
- 19.5.1 COMPANY SNAPSHOT
- 19.5.2 REVENUE ANALYSIS
- 19.5.3 COMPANY SHARE ANALYSIS
- 19.5.4 PRODUCT PORTFOLIO
- 19.5.5 RECENT DEVELOPMENTS
19.6 AUROBINDO PHARMA
- 19.6.1 COMPANY SNAPSHOT
- 19.6.2 REVENUE ANALYSIS
- 19.6.3 PRODUCT PORTFOLIO
19.7 BAXTER
- 19.7.1 COMPANY SNAPSHOT
- 19.7.2 REVENUE ANALYSIS
- 19.7.3 PRODUCT PORTFOLIO
19.8 FRESENIUS KABI USA
- 19.8.1 COMPANY SNAPSHOT
- 19.8.2 PRODUCT PORTFOLIO
- 19.8.3 RECENT DEVELOPMENTS
19.9 HIKMA PHARMACEUTICALS
- 19.9.1 COMPANY SNAPSHOT
- 19.9.2 REVENUE ANALYSIS
- 19.9.3 PRODUCT PORTFOLIO
- 19.9.4 RECENT DEVELOPMENT
19.10 PERRIGO COMPANY PLC
- 19.10.1 COMPANY SNAPSHOT
- 19.10.2 REVENUE ANALYSIS
- 19.10.3 PRODUCT PORTFOLIO
- 19.10.4 RECENT DEVELOPMENT
19.11 PFIZER INC.
- 19.11.1 COMPANY SNAPSHOT
- 19.11.2 REVENUE ANALYSIS
- 19.11.3 PRODUCT PORTFOLIO
- 19.11.4 RECENT DEVELOPMENTS
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD
- 19.12.1 COMPANY SNAPSHOT
- 19.12.2 REVENUE ANALYSIS
- 19.12.3 PRODUCT PORTFOLIO
- 19.12.4 RECENT DEVELOPMENT
19.13 TEVA PHARMACEUTICALS USA, INC.
- 19.13.1 COMPANY SNAPSHOT
- 19.13.2 REVENUE ANALYSIS
- 19.13.3 PRODUCT PORTFOLIO
- 19.13.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF TABLES

TABLE 1 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 2 IMPACT OF DELAY IN APPROVAL PROCESS
TABLE 3 EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 4 EUROPE DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 EUROPE DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 EUROPE DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 EUROPE DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 13 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 14 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 17 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 18 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 19 EUROPE MILD TO MODERATE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 EUROPE SEVERE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 22 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 27 EUROPE PRESCRIPTION IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 28 EUROPE OVER-THE-COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 EUROPE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 30 EUROPE MALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 EUROPE FEMALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 EUROPE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 33 EUROPE ADULT IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 EUROPE PEDIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 35 EUROPE GERIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 37 EUROPE HOSPITAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 EUROPE SPECIALITY CLINICS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 39 EUROPE HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 EUROPE RETAIL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 EUROPE HOSPITAL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 EUROPE ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 EUROPE DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 46 EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 47 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 50 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 51 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 53 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 54 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 55 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 56 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 59 EUROPE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 60 EUROPE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 61 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 62 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 63 FRANCE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 64 FRANCE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 65 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 67 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 68 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 70 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 71 FRANCE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 72 FRANCE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 73 FRANCE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 FRANCE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 FRANCE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 76 FRANCE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 77 FRANCE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 78 FRANCE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 79 FRANCE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 80 GERMANY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 81 GERMANY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 84 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 85 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 87 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 88 GERMANY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 89 GERMANY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 90 GERMANY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 GERMANY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 GERMANY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 93 GERMANY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 94 GERMANY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 95 GERMANY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 96 GERMANY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 97 SPAIN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 98 SPAIN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 101 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 102 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 104 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 105 SPAIN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 106 SPAIN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 107 SPAIN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 SPAIN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 SPAIN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 110 SPAIN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 111 SPAIN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 112 SPAIN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 113 SPAIN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 114 U.K. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 115 U.K. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 117 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 118 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 119 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 120 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 121 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 122 U.K. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 123 U.K. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 124 U.K. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 125 U.K. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 U.K. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 127 U.K. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 128 U.K. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 129 U.K. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 130 U.K. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 131 BELGIUM DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 132 BELGIUM DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 133 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 135 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 136 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 138 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 139 BELGIUM DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 140 BELGIUM DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 141 BELGIUM PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 142 BELGIUM ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 BELGIUM DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 144 BELGIUM DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 145 BELGIUM DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 146 BELGIUM DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 147 BELGIUM DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 148 ITALY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 149 ITALY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 151 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 152 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 153 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 155 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 156 ITALY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 157 ITALY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 158 ITALY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 ITALY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 ITALY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 161 ITALY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 162 ITALY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 163 ITALY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 164 ITALY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 165 NETHERLANDS DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 166 NETHERLANDS DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 169 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 170 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 171 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 172 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 173 NETHERLANDS DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 174 NETHERLANDS DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 175 NETHERLANDS PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 176 NETHERLANDS ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 177 NETHERLANDS DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 178 NETHERLANDS DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 179 NETHERLANDS DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 180 NETHERLANDS DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 181 NETHERLANDS DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 182 RUSSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 183 RUSSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 186 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 187 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 189 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 190 RUSSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 191 RUSSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 192 RUSSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 193 RUSSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 RUSSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 195 RUSSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 196 RUSSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 197 RUSSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 198 RUSSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 199 SWITZERLAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 200 SWITZERLAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 201 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 203 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 204 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 206 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 207 SWITZERLAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 208 SWITZERLAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 209 SWITZERLAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 210 SWITZERLAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 211 SWITZERLAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 212 SWITZERLAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 213 SWITZERLAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 214 SWITZERLAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 215 SWITZERLAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 216 TURKEY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 217 TURKEY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 220 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 221 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 223 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 224 TURKEY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 225 TURKEY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 226 TURKEY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 227 TURKEY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 TURKEY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 229 TURKEY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 230 TURKEY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 231 TURKEY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 232 TURKEY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 233 REST OF EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

LIST OF FIGURES

FIGURE 1 EUROPE DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE DENGUE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE DENGUE TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE DENGUE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 11 GROWING PHARMACEUTICAL INDUSTRY IS DRIVING THE GROWTH OF THE EUROPE DENGUE TREATMENT MARKET FROM 2024 TO 2031
FIGURE 12 ON THE BASIS OF STRAINS, THE DENV-2 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DENGUE TREATMENT MARKET IN 2024 AND 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE DENGUE TREATMENT MARKET
FIGURE 14 FINANCIAL BUDGET FOR VECTOR-BORNE -DISEASES INCLUDING DENGUE IN INDIA
FIGURE 15 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, 2023
FIGURE 16 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, 2024-2031 (USD MILLION)
FIGURE 17 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2024-2031)
FIGURE 18 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 EUROPE DENGUE TREATMENT MARKET: BY TYPE, 2023
FIGURE 20 EUROPE DENGUE TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 21 EUROPE DENGUE TREATMENT MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 22 EUROPE DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, 2023
FIGURE 24 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, 2024-2031 (USD MILLION)
FIGURE 25 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2024-2031)
FIGURE 26 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 27 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 28 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 29 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 30 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 31 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2023
FIGURE 32 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
FIGURE 33 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)
FIGURE 34 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 35 EUROPE DENGUE TREATMENT MARKET: BY GENDER, 2023
FIGURE 36 EUROPE DENGUE TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)
FIGURE 37 EUROPE DENGUE TREATMENT MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 38 EUROPE DENGUE TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 EUROPE DENGUE TREATMENT MARKET: BY AGE, 2023
FIGURE 40 EUROPE DENGUE TREATMENT MARKET: BY AGE, 2024-2031 (USD MILLION)
FIGURE 41 EUROPE DENGUE TREATMENT MARKET: BY AGE, CAGR (2024-2031)
FIGURE 42 EUROPE DENGUE TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 43 EUROPE DENGUE TREATMENT MARKET: BY END USER, 2023
FIGURE 44 EUROPE DENGUE TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 45 EUROPE DENGUE TREATMENT MARKET: BY END USER, CAGR (2024-2031)
FIGURE 46 EUROPE DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 48 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 49 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 50 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 EUROPE DENGUE TREATMENT MARKET: SNAPSHOT (2023)
FIGURE 52 EUROPE DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)